Document is current
Any future updates will be listed below
-
Authors
Siemionow, Maria https://orcid.org/0000-0001-6372-6122
Brodowska, Sonia https://orcid.org/0000-0002-0546-0060
Langa, Paulina https://orcid.org/0000-0002-0334-1391
Zalants, Kristina https://orcid.org/0000-0002-1914-9812
Kozlowska, Katarzyna https://orcid.org/0000-0002-0542-9960
Grau-Kazmierczak, Wictoria
Heydemann, Ahlke https://orcid.org/0000-0002-2626-3787
-
Funding
Funding for this research was provided by:
University of Illinois Chancellor’s Innovation Fund (CIF) Proof of Concept Award.
- License Information
-
More Information
Article History
Received: 1 May 2022
Accepted: 4 July 2022
First Online: 17 August 2022
Declarations
:
: MS is CMO and shareholder of Dystrogen Therapeutics SA, the company that holds a license for DEC Therapy. The author declares a potential conflict of interest. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). AH is the adviser to Dystrogen Therapeutics. The authors M.S., S.B., P.L., K.Z., K.K., W.G-K. and A.H., do not have any non-financial conflict of interest.
: This study was approved by the Institutional Animal Care and Use Committee (IACUC) of University of Illinois at Chicago, which is accredited by the American Association for the Accreditation of Laboratory Animal Care (AAALAC).
